Physician profile
Karin Boeck
NPI 1104817774
$4,036.45
in general payments reported to CMS, 2019-2025
25 companies · $582 in 2025
The $582 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $338 · 2021: $883 · 2022: $565 · 2023: $868 · 2024: $681 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102 · Education: $28.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.50 |
| Education | $28.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,173.82 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $633.47 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $315.83 | 2021-2025 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.69 | 2020-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $216.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $215.91 | 2019-2025 | Farxiga |
| Pfizer INC. | $193.33 | 2019-2025 | |
| Exact Sciences Corporation | $121.64 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $107.68 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $101.73 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $91.64 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $77.59 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $73.79 | 2021-2023 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $71.09 | 2021 | |
| Janssen Pharmaceuticals, INC | $67.73 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $61.48 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $48.24 | 2024-2025 | Opsumit, Uptravi |
| Sumitomo Pharma America, INC. | $44.12 | 2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $43.11 | 2023 | Rexulti |
| Astellas Pharma US INC | $32.72 | 2023 | Veozah |
| Axsome Therapeutics, INC. | $22.23 | 2025 | Auvelity |
| Merck Sharp & Dohme LLC | $14.64 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.51 | 2019 | |
| Amarin Pharma, INC. | $13.35 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Boeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.